Next Article in Journal
Qigong Exercise May Reduce Serum TNF-α Levels and Improve Sleep in People with Parkinson’s Disease: A Pilot Study
Next Article in Special Issue
Eryngium foetidum L. Essential Oils: Chemical Composition and Antioxidant Capacity
Previous Article in Journal
Current Usage of Traditional Chinese Medicine for Breast Cancer—A Narrative Approach to the Experiences of Women with Breast Cancer in Australia—A Pilot Study
Previous Article in Special Issue
Antimicrobial, Antioxidant, and Cytotoxic Activities of Ocimum forskolei and Teucrium yemense (Lamiaceae) Essential Oils
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antibacterial and Antifungal Activity of Essential Oils against Pathogens Responsible for Otitis Externa in Dogs and Cats

1
Department of Veterinary Science, University of Pisa, viale delle Piagge 2, 56124 Pisa, Italy
2
Centro Interdipartimentale di Ricerca “Nutraceutica e Alimentazione per la Salute”, University of Pisa, via del Borghetto 80, 56124 Pisa, Italy
3
Department of Pharmacy, University of Pisa, via Bonanno 6, 56126 Pisa, Italy
*
Author to whom correspondence should be addressed.
Medicines 2017, 4(2), 21; https://doi.org/10.3390/medicines4020021
Submission received: 2 March 2017 / Revised: 7 April 2017 / Accepted: 18 April 2017 / Published: 21 April 2017

Abstract

:
Background: Essential oils (EOs) are recommended by some veterinarians to treat otitis externa in pets, but data about their efficacy in scientific literature are very scant. Methods: Nine commercial EOs, from roman chamomile (Anthemis nobilis L.), star anise (Illicium verum), lavender (Lavandula hybrida), litsea (Litsea cubeba (Lour.) Pers.), basil (Ocimum basilicum L.), oregano (Origanum vulgare L. subsp. hirticum), rosemary (Rosmarinus officinalis L.), clary sage (Salvia sclarea L.), and thyme (Thymus vulgaris L.) were tested against bacterial and fungal pathogens previously isolated from dogs and cats with otitis externa. In particular, the analyses were carried out against Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus pseudointermedius, Aspergillus niger, Aspergillus fumigatus, Aspergillus terreus, Candida albicans, Candida tropicalis, Trichosporon sp., and Rhodotorula sp. Results: O. vulgare and S. sclarea showed superior antibacterial activity, even if not against all the strains. Trichosporon sp., C. albicans, and A. terreus were insensitive to most Eos, while other yeasts and molds showed different degrees of sensitivity. In particular, most fungi were inhibited by O. vulgare and R. officinalis. Conclusions: The obtained results suggest that some EOs could be included in treatment as an alternative therapeutic option in bacterial otitis complicated by fungi, in association with conventional drugs.

1. Introduction

Otitis externa is an inflammation of the external ear canal. Several predisposing factors in dogs and cats would be anatomic breed conformation, immunologic and endocrinopathic conditions, foreign material, trauma, and treatments. Various microorganisms can colonize the external ear canal, and they can proliferate with damage or inflammation due to primary factors [1]. Bacteria, yeasts, and parasites are common causes of otitis externa.
Among bacteria, staphylococci—mainly Staphylococcus pseudointermedius (formerly Staphylococcus intermedius [2]) and Staphylococcus aureusx—and Pseudomonas spp. are often isolated from ears of dogs and cats with acute or chronic otitis externa.
About 27% of cases of otitis externa are reported as being caused by fungi, mainly by Malassezia pachydermatis [3]. Other fungi more or less frequently involved are Aspergillus niger, Aspergillus fumigatus, Aspergillus terreus [4], and several yeasts, such as Candida albicans [5,6], Candida parapsilosis, Trichosporon cutaneum, and Cryptococcus laurentii [7], as well as Candida tropicalis [6,8] and Rhodotorula [9].
Antibiotic and/or antifungal treatments do not always resolve otitis externa in pets; conversely, they can worsen the situation, causing secondary and recurring infections.
The use of some essential oils (EOs) against otitis externa in pets is currently recommended by some veterinarians that—based on their experience—obtained good results in the treatment of these infections. However, data about the efficacy of EOs against bacteria and yeasts related to canine and/or feline otitis are not available in the scientific literature, with the exception of reports on M. pachydermatis otitis externa [10]; furthermore, information about human cases are very scant [11,12,13].
The aim of this study was to evaluate the in vitro antibacterial and antifungal activities of EOs against the most frequent pathogens isolated from the ears of dogs and cats with otitis externa. EOs have been selected for their effectiveness as reported in literature and for their availability on the market.

2. Material and Methods

2.1. Essential Oils

The study was performed employing the following nine EOs: roman chamomile (Anthemis nobilis L.), star anise (Illicium verum), lavender (Lavandula hybrida), litsea (Litsea cubeba (Lour.) Pers.), basil (Ocimum basilicum L.), oregano (Origanum vulgare L. subsp. hirticum), rosemary (Rosmarinus officinalis L.), clary sage (Salvia sclarea L.), and thyme (Thymus vulgaris L.).
All EOs were acquired from the producer (FLORA®, Pisa, Italy). They were maintained at 4 °C in dark glass vials and were microbiologically analyzed for quality control before use.

2.2. Gas Chromatography–Mass Spectrometry Analysis

The GC analysis was performed as previously described [14].

2.3. Antibacterial Activity

2.3.1. Bacterial Strains

Each EO was tested against three bacterial strains: Pseudomonas aeruginosa, S. aureus, and S. pseudointermedius. All the isolates were previously obtained from cases of otitis externa of dogs and/or cats, typed, and stored at −80 °C in glycerol broth.

2.3.2. Agar Disc Diffusion Method

Antibacterial activity of each EO was tested by Kirby-Bauer agar disc diffusion method following the previously described procedures [15,16].
Bacterial strains were also tested by Kirby-Bauer method to evaluate their in vitro sensitivity to the following antibiotics (Oxoid): amikacin (30 µg), amoxycillin–clavulanic acid (30 μg), ampicillin (10 µg), cefotaxime (30 µg), ceftazidime (30 µg), cephalexin (30 µg), ciprofloxacin (5 µg), erythromycin (10 µg), enrofloxacin (5 µg), streptomycin (10 µg), sulphametoxazole–trimethoprim (25 µg), and tetracycline (30 µg). The results were interpreted as indicated by the National Committee for Clinical Laboratory Standards (NCCLS) [17].

2.3.3. Minimum Inhibitory Concentration

Each bacterial strain resulting sensitive to the EOs in the Kirby-Bauer test was submitted to the determination of the minimum inhibitory concentration (MIC).
MIC was tested with agar disc diffusion method, adding 10 µL of 10%, 5%, 2.5%, 1.25%, 0.62%, 0.31% (v/v) of each EO. Results were successively calculated as µg/µL. All tests were performed in triplicate.

2.4. Antimycotic Activity

2.4.1. Fungal Strains

Clinical isolates of A. niger, A. fumigatus, A. terreus, C. albicans, C. tropicalis, Trichosporon sp., and Rhodotorula sp. obtained from dogs and cats suffering from otitis externa were employed for testing. Molds were stored at −20 °C on potato dextrose agar, and yeasts were maintained in distilled water at room temperature.

2.4.2. Microdilution Test

MICs were determined by a microdilution test carried out as reported elsewhere [15], starting from a dilution of 5% (v/v), following the methods described by Clinical and Laboratory Standards Institute M38A2 [18] for molds and Clinical and Laboratory Standards Institute M27A3 [19] for yeasts.

3. Results

3.1. Gas Chromatography–Mass Spectrometry Analysis

The composition of the assayed EOs is presented in Table 1. All these oils were rich in monoterpenes, except for A. nobilis, where non-terpenic esters such as isobutyl angelate (34.5%) and isoamyl angelate (18.7%) were the most represented constituents. The main terpenes identified in the EO of O. vulgare and T. vulgaris were carvacrol (65.9%) and thymol (52.6%), respectively, followed by p-cymene (15.3%) only in T. vulgaris. Linalyl acetate was evidenced in S. sclarea as the main constituent (54.7%). Linalool was the most important compound in the EO of O. basilicum and L. hybrida (46.0% and 31.5%, respectively). It is also important to highlight the presence of eugenol in O. basilicum with a significant percentage (11.5%) and linalyl acetate in L. hybrida (26.8%). The EO of I. verum was characterized by the presence of a good amount of anethol (89.8%). More represented constituents of L. cubeba were neral and geranial (32.5% and 36.4%, respectively), while R. officinalis was characterized by 37.9% of α-pinene, followed by 1,8-cineole (22.0%).

3.2. Antibacterial Activity

The results obtained in this investigation showed that the assayed EOs had different degrees of growth inhibition against the three tested bacterial isolates (Table 2).
A. nobilis, I. verum, L. hybrida, and L. cubeba had no activity against the three tested bacteria.
S. sclarea showed good activity against S. pseudointermedius, with an MIC value of 2.23 µg/µL and scarce activity against P. aeruginosa (MIC of 17.86 µg/µL). O. vulgare inhibited the growth of S. aureus and S. pseudointermedius, with MIC values of 2.36 µg/µL and 1.18 µg/µL, respectively; on the other hand, no activity was observed against P. aeruginosa. Very low antimicrobial activity was observed for the remaining EOs. DMSO, tested as negative control, did not cause growth inhibition.
P. aeruginosa was resistant to eleven antibiotics and susceptible only to amikacin; S. aureus were susceptible to tetracycline, amoxicillin–clavulanic acid, erythromycin, and sulphametoxazole–trimethoprim; S. pseudointermedius was susceptible only to amoxicillin–clavulanic acid (Table 3).

3.3. Antimycotic Activity

Tested fungal isolates showed different sensitivity patterns to assayed EOs. The overall lowest MIC values were reported for O. vulgare and R. officinalis. S. sclarea, R. officinalis, and T. vulgaris had MIC values <0.3 µg/µL against C. tropicalis, while O. vulgare showed a good antifungal activity against aspergilli. Trichosporon sp. appeared to be sensitive to R. officinalis only, while Rhodotorula sp. was inhibited from R. officinalis and O. vulgare. This latter EO was the sole active when tested against C. albicans. Detailed results are reported in Table 4.

4. Discussion

The bacterial strains analyzed in this study have previously been isolated from pets with chronic otitis externa. These strains resulted multiresistant to several antibiotics, and for this reason they caused problems in therapy.
S. aureus has been isolated from several body sites of dogs and cats—in particular from skin, anterior nares, and anal region. Staphylococci seem to be transferred from the nose and mouth of the dog to its coat and ears by grooming and pruritic behaviors [20].
S. pseudointermedius is part of the microflora of the upper respiratory tract, mucosal, and skin surfaces of dogs and cats; moreover, it may be an invasive pathogen determining some pathologies, including otitis. Resistance of S. aureus and S. pseudintermedius to classical antibiotics used in clinical veterinary therapy is an increasing threat [21].
P. aeruginosa is an opportunistic, ubiquitous bacterial pathogen that can be isolated from the tissue of healthy animals, and has been determined to be the distinct cause of several infections, including chronic otitis externa. An increasing number of P. aeruginosa strains resistant to several antibiotics has been observed in recent years [22].
The results of this study show that not all EOs have activity against the tested bacterial strains.
EO of O. vulgare gave good results only against staphylococci, in accordance with other studies that consider this EO as an effective antistaphylococcal natural product.
The major compounds of oregano EO—carvacrol, thymol, and terpenoids—seem to determine the antimicrobial activity [23], and it is speculated that they disrupt the membrane of bacteria; in particular, they sensitize the phospholipid bilayer of the cell membrane, increasing the permeability and leakage of vital intracellular constituents [24].
Previous studies found that S. sclarea is active against staphylococci, including S. aureus [25], whereas we found that the tested S. aureus strain was resistant. However, data about the antimicrobial activity of S. sclarea are mainly related to food pathogens, whereas no information is available about its clinical use.
Trichosporon sp., C. albicans, and A. terreus were insensitive to most EOs evaluated in the present study, while other fungi showed different degrees of sensitivity. C. tropicalis was reported as sensitive when tested against S. sclarea, R. officinalis, and T. vulgaris, confirming previously reported data concerning this latter EO [15,26].
O. vulgare has a known antimicrobial effect [26,27] due to the high amount of carvacrol, confirming the results of our study.
R. officinalis yielded interesting results showing its efficacy, which appear to be in agreement with Fu et al. [28] for A. niger, but not for C. albicans. Our results confirm the effectiveness of O. vulgare against A. niger and Rhodotorula sp., and the ineffectiveness of I. verum against A. niger, reported by Elgayyar et al. [27], but would not corroborate data referred to both O. basilicum and R. officinalis, as well as the efficacy of I. verum against Rhodotorula sp.
Molds and yeasts tested in the present report were cultured from affected animals’ ears. Even if antifungal drug resistance is not a common feature involving these agents, such alternative treatment based on natural products could achieve the owners’ approval [10], but the choice of an EOs-based treatment should take into account the identification of fungal organisms responsible for the disease in order to select the most suitable product for treatment. In fact, the results obtained in the present study would suggest that the analyzed EOs are not always able to replace antibiotics or antimycotic drugs to treat such infections, being that their effectiveness is strictly related to the pathogen involved. For example, in the case of P. aeruginosa isolate, the treatment with amikacin resulted better than the use of EOs that, although active, had high MIC values (from 17.86 µg/µL to 18.34 µg/µL).
In the light of the above considerations, the first choice option would take into account the causative agents of otitis with isolation and typing of the etiologic agent; successively, it would be important to carry out an antimicrobial susceptibility test to select an appropriate therapy. EOs can represent a good therapeutic tool, but considered that their efficacy is strongly related to the bacterial strain, it could be useful to evaluate the in vitro activity of different EOs in order to select a natural product effective against the pathogen and that could improve the efficacy treatment.
In conclusion, EOs could be scheduled as an alternative therapeutic option in bacterial otitis complicated by fungi in association with conventional drugs.

Author Contributions

V.V.E. and F.M. conceived and designed the experiments and wrote the paper; S.N., F.B. and B.N. performed the experiments; V.V.E., F.M. and L.P. analyzed the data.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Greene, C.E. Otitis externa. In Infectious Diseases of the Dogs and Cats, 3rd ed.; Greene, C.E., Ed.; Saunders Elsevier: St. Louis, MO, USA, 2006; pp. 815–823. [Google Scholar]
  2. Devriese, L.A.; Hermans, K.; Baele, M.; Haesebrouck, F. Staphylococcus pseudintermedius versus Staphylococcus intermedius. Vet. Microbiol. 2009, 133, 206–207. [Google Scholar] [CrossRef] [PubMed]
  3. Kuttin, E.S.; Glas, I. Mycotic otitis externa in animals. Mycoses 1985, 28, 61–68. [Google Scholar] [CrossRef]
  4. Goodale, E.C.; Outerbridge, C.A.; White, S.D. Aspergillus otitis in small animals—A retrospective study of 17 cases. Vet. Dermatol. 2016, 27. [Google Scholar] [CrossRef] [PubMed]
  5. Pal, M.; Rao, N.M. Canine otitis due to Candida albicans. Indian Vet. J. 2001, 78, 150–151. [Google Scholar]
  6. Brito, E.H.; Brilhante, R.S.; Cordeiro, R.A.; Sidrim, J.J.; Fontenelle, R.O.; Melo, L.M.; Albuquerque, E.S.; Rocha, M.F. PCR-AGE, automated and manual methods to identify Candida strains from veterinary sources: A comparative approach. Vet. Microbiol. 2009, 18, 318–322. [Google Scholar] [CrossRef] [PubMed]
  7. Bernardo, F.M.; Martins, H.M.; Martins, M.L. A survey of mycotic otitis externa of dogs in Lisbon. Rev. Iberoam. Micol. 1998, 15, 163–165. [Google Scholar] [PubMed]
  8. Gedek, B.; Brutzel, K.; Gerlach, R.; Netzer, F.; Rocken, H.; Unger, H.; Symoens, J. The role of Pityrosporum pachydermatis in otitis externa of dogs: Evaluation of a treatment with miconazole. Vet. Rec. 1979, 104, 138–140. [Google Scholar] [CrossRef] [PubMed]
  9. De Bona, E.; Ubiratan Paz Telesca, S.; Meneghello Fuentefria, A. Occurrence and identification of yeasts in dogs external ear canal with and without otitis. Rev. MVZ Cordoba 2012, 17, 3059–3064. [Google Scholar]
  10. Nardoni, S.; Pistelli, L.; Baronti, I.; Najar, B.; Pisseri, F.; Bandeira Reidel, R.V.; Papini, R.; Perrucci, S.; Mancianti, F. Traditional Mediterranean plants: Characterization and use of an essential oils mixture to treat Malassezia otitis externa in atopic dogs. Nat. Prod. Res. 2016, 5, 1–4. [Google Scholar] [CrossRef] [PubMed]
  11. Panahi, Y.; Akhavan, A.; Sahebkar, A.; Hosseini, S.M.; Taghizadeh, M.; Akbari, H.; Sharif, M.R.; Imani, S. Investigation of the effectiveness of Syzygium aromaticum, Lavandula angustifolia and Geranium robertianum essential oils in the treatment of acute external otitis: A comparative trial with ciprofloxacin. J. Microbiol. Immunol. Infect. 2014, 47, 211–216. [Google Scholar] [CrossRef] [PubMed]
  12. Nogueira, J.C.; Diniz Mde, F.; Lima, E.O. In vitro antimicrobial activity of plants in acute otitis externa. Braz. J. Otorhinolaryngol. 2008, 74, 118–124. [Google Scholar] [CrossRef]
  13. Farnan, T.B.; McCallum, J.; Awa, A.; Khan, A.D.; Hall, S.J. Tea tree oil: In vitro efficacy in otitis externa. J. Laryngol. Otol. 2005, 119, 198–201. [Google Scholar] [CrossRef] [PubMed]
  14. Bandeira Reidel, R.V.; Melai, B.; Cioni, P.L.; Flamini, G.; Pistelli, L. Aroma profile of Rubus ulmifolius flowers and fruits during different ontogenetic phases. Chem. Biodiv. 2016, 13, 1776–1784. [Google Scholar] [CrossRef] [PubMed]
  15. Ebani, V.V.; Nardoni, S.; Bertelloni, F.; Giovanelli, S.; Rocchigiani, G.; Pistelli, L.; Mancianti, F. Antibacterial and antifungal activity of essential oils against some pathogenic bacteria and yeasts shed from poultry. Flav. Fragr. J. 2016, 31, 302–309. [Google Scholar] [CrossRef]
  16. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests, Approved Standard-Eleventh Edition; CLSI Document; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2012. [Google Scholar]
  17. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Twelfth International Supplement; NCCS: Wayne, PA, USA, 2002. [Google Scholar]
  18. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, Approved Standard, 2nd ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2008. [Google Scholar]
  19. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard—Third Edition; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2008. [Google Scholar]
  20. Boost, M.V.; O’Donoghue, M.M.; James, A. Prevalence of Staphylococcus aureus carriage among dogs and their owners. Epidemiol. Infect. 2008, 136, 953–964. [Google Scholar] [CrossRef] [PubMed]
  21. Lima, C.O.; Barreto, H.M.; de Oliveira Lima, E.; de Souza, E.L.; de Siqueira Junior, J.P. Antimicrobial effect of the essential oil from Rosmarinus officinalis L. against Staphylococcus pseudintermedius isolated from dogs. Rev. Bras. Biocienc. 2013, 11, 280–283. [Google Scholar]
  22. Mekić, S.; Matanović, K; Šeol, B. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates from dogs with otitis externa. Vet. Rec. 2011, 169, 125–128. [Google Scholar] [CrossRef] [PubMed]
  23. Barros, J.C.; De Conceicão, M.L.; Da Gomes Neto, N.J.; Costa, C.V.; Da Siqueira Júnior, J.P.; Basílio Junior, I.D.; De Souza, E.L. Interference of Origanum vulgare L. essential oil on the growth and some physiological characteristics of Staphylococcus aureus strains isolated from foods. LWT—Food Sci. Technol. 2009, 42, 1139–1143. [Google Scholar] [CrossRef]
  24. Kim, J.; Marshall, M.R.; Wei, C. Antibacterial activity of some essential oil components against five foodborne pathogens. J. Agric. Food Chem. 1995, 43, 2839–2845. [Google Scholar] [CrossRef]
  25. Kuźma, L.; Róžalski, M.; Walencka, E.; Róžalska, B.; Wysokińska, H. Antimicrobial activity of diterpenoids from hairy roots of Salvia sclarea L.: Salvipisone as a potential anti-biofilm agent active against antibiotic resistant Staphylococci. Phytomedicine 2007, 14, 31–35. [Google Scholar] [CrossRef] [PubMed]
  26. Pozzatti, P.; Scheid, L.A.; Spader, T.B.; Atayde, M.L.; Santurio, J.M.; Alves, S.H. In vitro activity of essential oils extracted from plants used as spices against fluconazole-resistant and fluconazole-susceptible Candida spp. Can. J. Microbiol. 2008, 54, 950–956. [Google Scholar] [CrossRef] [PubMed]
  27. Elgayyar, M.; Draughon, F.A.; Golden, D.A.; Mount, J.R. Antimicrobial activity of essential oils from plants against selected pathogenic and saprophytic microorganisms. J. Food Prot. 2001, 64, 1019–1024. [Google Scholar] [CrossRef] [PubMed]
  28. Fu, Y.; Zu, Y.; Chen, L.; Shi, X.; Wang, Z.; Sun, S.; Efferth, T. Antimicrobial activity of clove and rosemary essential oils alone and in combination. Phytother. Res. 2007, 21, 989–994. [Google Scholar] [CrossRef] [PubMed]
Table 1. Relative percentage of the main constituents of tested essential oils (EOs).
Table 1. Relative percentage of the main constituents of tested essential oils (EOs).
N.ClassComponentRIA.nO.vO.bS.sT.vI.vR.oL.cL.h
1estpropyl butanoate8985.5
2mhtricyclene926 1.4 1.5
3mhα-pinene9401.2 37.9
4mhcamphene953 5.4
5mhsabinene976 1.0
6estisopropyl tiglate9761.7
7mhβ-pinene980 5.01.2
8nt6-methyl-5-hepten-2-one985 1.5
9mhmyrcene991 2.2 1.6
10estisobutyl isovalerate10051.3
11est2-methylbutyl isobutyrate10154.5
12mhα-terpinene1018 2.1
13mho-cymene1026 1.1
14mhp-cymene1026 9.3 15.3
15mhlimonene1031 3.93.316.3
16om1,8-cineole1033 5.9 22.02.37.7
17mh(Z) β-ocimene1040 1.2
18mh(E) β-ocimene1050 2.1
19estisobutyl angelate105334.5
20mhγ-terpinene1062 5.3 2.9 0.5
21mhartemisia ketone10657.4
22omcis-linalool oxide (furanoid)1074 2.2
23omtrans-linalool oxide (furanoid)1088 1.8
24estisobutyl tiglate10931.5
25omtrans-sabinene hydrate1097 1.8 3.8
26omlinalool1098 46.08.1 1.531.5
27omtrans-pinocarveol11421.7
28omcamphor1143 7.6 7.3
29estpropyl tiglate11535.3
30estisoamyl angelate116218.7
31omborneol1165 1.6 2.0 2.1
32ompinocarvone11662.7
33omterpinen-4-ol1177 2.4 4.0
34omα-terpineol1189 2.1
35 unknown 1.7
36ppmethyl chavicol (=estragol)1195 1.1
37omthymol methyl ether1232 1.7
38omneral1240 32.5
39omlinalyl acetate1257 54.7 26.8
40omgeranial1270 36.4
41pp(E)-anethol1283 89.8
42omisobornyl acetate1285 1.6 3.3
43ombornyl acetate1285 2.4
44omthymol1290 52.6
45omcarvacrol1298 65.9
46om(E)-8-hydroxylinalool 1345 5.6
47om(Z)-8-hydroxylinalool1360 15.8
48ppeugenol1356 11.5
49shβ-elemene1392 2.2
50shβ-caryophyllene1418 3.7 6.8 4.1 2.2
51shtrans-α-bergamotene1437 3.6
52shα-guaiene1440 1.1
53sh(E)-β-farnesene1458 1.4
54shgermacrene D1481 3.5
55shα-bulnesene1505 2.0
56shtrans-γ-cadinene1513 2.8
57shδ-cadinene1524 1.0
58oscaryophyllene oxide1581 4.8 0.3
59os1,10-di-epi-cubenol1614 1.0
60ost-cadinol1640 5.8
61odsclareol2223 1.3
Total% 92.198.599.298.995.6100.097.499.4100.0
Legend: RI: Retention index measured on HP-5 column; Compounds present in percentage <1% were excluded from the table. A.n.: Anthemis nobilis; I.v.: Illicium verum; L.h.: Lavandula hybrid; L.c.: Litsea cubeba; O.b.: Ocimum basilicum; O.v.: Origanum vulgare subsp. hirticum; R.o.: Rosmarinus officinalis; S.s.: Salvia sclarea; T.v.: Thymus vulgaris; mh: monoterpene hydrocarbons; om: oxygenated monoterpenes; sh: sesquiterpene hydrocarbons; os: oxygenated sesquiterpenes; nt: non-terpenes; pp: phenylpropanoids; od: oxygenated diterpenes; est: non-terpenic esters.
Table 2. The inhibition zones obtained testing the selected bacterial strains against the assayed EOs.
Table 2. The inhibition zones obtained testing the selected bacterial strains against the assayed EOs.
Bacterial Strains
Staphylococcus aureusStaphylococcus pseudointermediusPseudomonas aeruginosa
Essential Oils
M SD M SD M SD
Anthemis nobilis0.0 ± 0.00.0 ± 0.00.0 ± 0.0
Illicium verum0.0 ± 0.00.0 ± 0.00.0 ± 0.0
Lavandula hybrida0.0 ± 0.00.0 ± 0.00.0 ± 0.0
Litsea cubeba0.0 ± 0.00.0 ± 0.00.0 ± 0.0
Ocimum basilicum0.0 ± 0.07.0 ± 0.0 18.0 ± 0.0 2
Origanum vulgare13.3 ± 0.6 317.3 ± 0.6 40.0 ± 0.0
Rosmarinus officinalis0.0 ± 0.00.0 ± 0.07.0 ± 0.0 5
Salvia sclarea0.0 ± 0.014.3 ± 0.6 68.0 ± 0.0 7
Thymus vulgaris8.3 ± 0.6 80.0 ± 0.00.0 ± 0.0
Legend: M: mean expressed in mm; MIC: minimum inhibitory concentration; SD: standard deviation. 1 MIC: 18.34 µg/µL; 2 MIC: 18.34 µg/µL; 3 MIC: 2.36 µg/µL; 4 MIC: 1.18 µg/µL; 5 MIC: 18.28 µg/µL; 6 MIC: 2.23 µg/µL; 7 MIC: 17.86 µg/µL; 8 MIC: 18.73 µg/µL.
Table 3. The inhibition zones (expressed in mm) obtained testing the selected bacterial strains against different antibiotics (standard deviation was equal to 0).
Table 3. The inhibition zones (expressed in mm) obtained testing the selected bacterial strains against different antibiotics (standard deviation was equal to 0).
Bacterial Strains
Staphylococcus aureusStaphylococcus pseudointermediusPseudomonas aeruginosa
Antibiotics
Amikacin7 (R)9 (R)17 (S)
Amoxycillin–clavulanic acid27 (S)26 (S)0 (R)
Ampicillin16 (R)15 (R)0 (R)
Ceftazidime0 (R)0 (R)0 (R)
Cephalexin0 (R)0 (R)0 (R)
Cephotaxime0 (R)0 (R)13 (R)
Ciprofloxacin10 (R)0 (R)0 (R)
Enrofloxacin14 (R)0 (R)0 (R)
Erythromycin17 (S)0 (R)0 (R)
Streptomycin0 (R)0 (R)0 (R)
Sulphametoxazole–trimethoprim24 (S)0 (R)0 (R)
Tetracycline20 (S)0 (R)0 (R)
Legend: S: susceptible; R: resistant.
Table 4. MIC values (expressed in µg/µL) of tested EOs versus selected fungal agents (standard deviation was equal to 0).
Table 4. MIC values (expressed in µg/µL) of tested EOs versus selected fungal agents (standard deviation was equal to 0).
Fungal Agents
Essential OilsCandida albicansCandida tropicalisAspergillus nigerAspergillus terreusAspergillus fumigatusTrichosporon sp.Rhodotorula sp.
Anthemis nobilis4.504.504.504.502.254.504.50
Illicium verum2.444.882.442.440.599.782.44
Lavandula hybrida4.254.252.12>8.508.50>8.504.25
Litsea cubeba4.432.210.532.210.188.864.43
Ocimum basilicum2.294.581.104.582.299.171.10
Origanum vulgare0.191.140.190.190.192.370.19
Rosmarinus officinalis9.140.290.29>9.140.290.460.29
Salvia sclarea1.070.182.234.462.23>8.93>8.93
Thymus vulgaris5.720.190.5611.715.7211.715.72

Share and Cite

MDPI and ACS Style

Ebani, V.V.; Nardoni, S.; Bertelloni, F.; Najar, B.; Pistelli, L.; Mancianti, F. Antibacterial and Antifungal Activity of Essential Oils against Pathogens Responsible for Otitis Externa in Dogs and Cats. Medicines 2017, 4, 21. https://doi.org/10.3390/medicines4020021

AMA Style

Ebani VV, Nardoni S, Bertelloni F, Najar B, Pistelli L, Mancianti F. Antibacterial and Antifungal Activity of Essential Oils against Pathogens Responsible for Otitis Externa in Dogs and Cats. Medicines. 2017; 4(2):21. https://doi.org/10.3390/medicines4020021

Chicago/Turabian Style

Ebani, Valentina V., Simona Nardoni, Fabrizio Bertelloni, Basma Najar, Luisa Pistelli, and Francesca Mancianti. 2017. "Antibacterial and Antifungal Activity of Essential Oils against Pathogens Responsible for Otitis Externa in Dogs and Cats" Medicines 4, no. 2: 21. https://doi.org/10.3390/medicines4020021

APA Style

Ebani, V. V., Nardoni, S., Bertelloni, F., Najar, B., Pistelli, L., & Mancianti, F. (2017). Antibacterial and Antifungal Activity of Essential Oils against Pathogens Responsible for Otitis Externa in Dogs and Cats. Medicines, 4(2), 21. https://doi.org/10.3390/medicines4020021

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop